尿激酶联合低分子肝素治疗结核性胸膜炎疗效观察  

Curative effect of urokinase combined with low molecular weight heparin on tuberculous pleurisy

作　　者：刘志辉[1] 郑东升[1] 

机构地区：[1]广州市白云区中医医院内二科,广东广州510470

出　　处：《现代临床医学》2017年第2期122-124,共3页Journal of Modern Clinical Medicine

摘　　要：目的:分析尿激酶联合低分子肝素治疗结核性胸膜炎的临床疗效。方法:选取2015年8月至2016年7月我院内科收治的30例抽液困难的结核性胸膜炎患者作为观察对象,随机分为治疗组与对照组,每组15例。对照组使用单药尿激酶治疗,治疗组则采用尿激酶联合低分子肝素治疗。观察比较2组患者临床疗效、胸腔积液、胸膜及肺功能的变化。结果:治疗组与对照组的总有效率为93.33%和73.33%,治疗组显著优于对照组(P<0.01)。治疗后,治疗组胸腔积液、胸膜粘连、胸膜厚度、用力肺活量(FVC)、1秒率(FEV1/FVC)的改善情况显著优于对照组(P<0.05或P<0.01)。结论:尿激酶联合低分子肝素治疗结核性胸膜炎具有较高的临床疗效,有助于提高患者的生活质量,值得在临床中推广使用。Objective： To analyze the efficacy of urokinase combined with low molecular heparin in the treatment of tuberculous pleurisy. Methods： From August 2015 to July 2016, 30 cases of tuberculous pleurisy of difficult drainage were randomly divided into treatment group and control group, 15 cases in each group. The control group used urokinase alone while the treatment group used urokinase combined with low molecular weight heparin. Clinical efficacy and the changes of pleural effusion, pleura and pulmonary function were observed and compared between the two groups. Results： The effective rate of the treatment group was 93.33%, which was significantly better than that of the control group （73.33 % , P 〈0. 01 ）. In addition, the treatment group showed better improvement in pleural effusion, pleural adhesion, pleural thickness, forced vital capacity（FVC） and one second rate （FEV1/FVC） than the control group（ P 〈 0. 05 or P 〈 0. 01 ）. Conclusion： Urokinase combined with low molecular weight heparin can achieve good clinical efficacy in the treatment of patients with tuberculous pleurisy and is helpful to improve their quality of life. Therefore, it is worthy of application and promotion in clinic.

关 键 词：尿激酶 低分子肝素 结核性胸膜炎 疗效 

分 类 号：R521.7[医药卫生—内科学]